Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.

Abstract

BACKGROUND:

Cerebrovascular accidents (CVAs), transient ischemic attacks (TIAs), and peripheral arterial disease (PAD) frequently coexist with coronary artery disease (CAD) and were previously reported to adversely affect the prognosis of patients with chronic CAD.

METHODS:

We examined the effect of prior CVA/TIA or PAD (extra-cardiac vascular disease [EVD]) on the outcome of 10,281 patients with acute coronary syndromes enrolled in the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 trial of the oral glycoprotein IIb/IIIa antagonist orbofiban plus aspirin versus aspirin alone. We evaluated mortality, recurrent cardiac events, and stroke and used multivariate analysis to control for differences in baseline characteristics.

RESULTS:

Patients with EVD were older, had more coronary risk factors, had a history of CAD, and received more intensive medical treatment at baseline. The acute event in these patients was more often unstable angina pectoris and less commonly Q-wave myocardial infarction. With coronary angiography, patients with prior EVD more often had multivessel disease. During the 10 months of follow-up, the presence of EVD was predictive of an increased hazard of death, reinfarction, recurrent ischemia, stroke, and a composite of these events. Despite the increased severity of the CAD and increased risk of events, patients with EVD were treated less frequently with beta-blockers and more frequently with calcium blockers. Despite patients with EVD having a 45% higher incidence of hypercholesterolemia, lipid-lowering agents were prescribed in a similar percentage of patients as patients without EVD.

CONCLUSION:

In patients with acute coronary syndromes, the presence of prior CVA, TIA, or PAD is associated with more extensive CAD and worse outcome. These patients appear to receive less aggressive treatment, which may explain, at least in part, their worse outcome.

• Authors: Gad Cotter, Christopher P Cannon, Carolyn H McCabe, Yoav Michowitz, Edo Kaluski, Andrew Charlesworth, Olga Milo, Jane Bentley, Alex Blatt, Rikardo Krakover, Reuven Zimlichman, Leonardo Reisin, Alon Marmor, Basil Lewis, Zvi Vered, Avi Caspi, Eugene Braunwald, OPUS-TIMI 16 Investigators
• Journal: American heart journal (Am Heart J) Vol. 145 Issue 4 Pg. 622-7 (Apr 2003) ISSN: 1097-6744 [Electronic] United States
• PMID: 12679757 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Platelet Aggregation Inhibitors
• Platelet Glycoprotein GPIIb-IIIa Complex
• Pyrrolidines
• orbofiban
• Alanine
• Aspirin

Topics

• Aged
• Alanine (therapeutic use)
• Aspirin (therapeutic use)
• Cerebrovascular Disorders (complications)
• Coronary Disease (complications, drug therapy)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Humans
• Multivariate Analysis
• Peripheral Vascular Diseases (complications)
• Platelet Aggregation Inhibitors (therapeutic use)
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
• Prospective Studies
• Pyrrolidines (therapeutic use)
• Regression Analysis
• Risk Factors
• Treatment Outcome